The RELATIVITY-098 trial showed no RFS improvement with nivolumab plus relatlimab versus nivolumab alone in resected stage III-IV melanoma. The trial was terminated as it failed to meet its primary ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell ...

Flipping the standard doses of nivolumab plus ipilimumab for patients with advanced melanoma may improve survival with less toxicity, a real-world study finds.

Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS) in patients with completely resected Merkel cell carcinoma (MCC), interim results ...

Given this paucity of reports we hereby summarize our experience using nivolumab before or after allo-HCT. Five subjects were treated; patient characteristics are listed in Table 1; transplant ...

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Among 121 treated patients, ...